PMID- 21819487
OWN - NLM
STAT- MEDLINE
DCOM- 20120719
LR  - 20151113
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Linking)
VI  - 19
IP  - 2
DP  - 2012 Feb
TI  - Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly 
      patients with Parkinson's disease.
PG  - 258-64
LID - 10.1111/j.1468-1331.2011.03484.x [doi]
AB  - BACKGROUND: Rasagiline, an MAO-B inhibitor, is indicated for the treatment of 
      Parkinson's disease (PD). In this post hoc analysis, the efficacy, safety and 
      tolerability of rasagiline as an adjunct to levodopa were compared with placebo 
      in elderly (>/=70 years) and younger (<70 years) patients with PD. METHODS: Data 
      were pooled from the Parkinson's Rasagiline: Efficacy and Safety on the Treatment 
      of 'OFF' and Lasting effect in Adjunct therapy with Rasagiline Given Once daily 
      randomized, double-blind, placebo-controlled trials with the primary efficacy 
      end-point being the reduction from baseline in daily OFF time. Secondary efficacy 
      end-points included scores for Clinical Global Improvement (CGI)-Examiner during 
      ON time, Unified Parkinson's Disease Rating Scale (UPDRS)-ADL during OFF time, 
      UPDRS-Motor during ON time and total daily ON time with and without troublesome 
      dyskinesia. Tolerability was evaluated from adverse events (AEs) in the two age 
      groups. RESULTS: Rasagiline decreased daily OFF time versus placebo (P<0.01) and 
      improved CGI-Examiner score (P=0.001) and UPDRS-Motor ON score (P<0.05). Changes 
      in UPDRS-ADL OFF score and total daily ON time without dyskinesia also favoured 
      rasagiline but were not significant. Between-group comparisons (>/=70 vs. <70 
      years) showed that efficacy was unaffected by age for all end-points (P>0.1), and 
      rasagiline was well tolerated amongst both groups of patients with a comparable 
      incidence of total and dopaminergic AEs (P>0.1). CONCLUSIONS: Adjunct rasagiline 
      is efficacious and well tolerated in elderly non-demented patients (>/=70 years) 
      with moderate to advanced PD. Confirmation of the efficacy and safety of 
      rasagiline in the elderly patient subgroup is especially relevant because of the 
      increasing number of elderly patients with PD.
CI  - (c) 2011 The Author(s). European Journal of Neurology (c) 2011 EFNS.
FAU - Tolosa, E
AU  - Tolosa E
AD  - Neurology Service, Hospital Clinic Universitari, Centro de Investigacion 
      Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), IDIBAPS, 
      Universitat de Barcelona, Spain. etolosa@clinic.ub.es
FAU - Stern, M B
AU  - Stern MB
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110805
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Indans)
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 0 (Neuroprotective Agents)
RN  - 003N66TS6T (rasagiline)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antiparkinson Agents/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Indans/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Monoamine Oxidase Inhibitors/adverse effects/*therapeutic use
MH  - Neuroprotective Agents/adverse effects/*therapeutic use
MH  - Parkinson Disease/*drug therapy
MH  - Treatment Outcome
EDAT- 2011/08/09 06:00
MHDA- 2012/07/20 06:00
CRDT- 2011/08/09 06:00
PHST- 2011/08/09 06:00 [entrez]
PHST- 2011/08/09 06:00 [pubmed]
PHST- 2012/07/20 06:00 [medline]
AID - 10.1111/j.1468-1331.2011.03484.x [doi]
PST - ppublish
SO  - Eur J Neurol. 2012 Feb;19(2):258-64. doi: 10.1111/j.1468-1331.2011.03484.x. Epub 
      2011 Aug 5.